Changes in renal, bone, lipid, and inflammation markers in HIV-1 patients after combination antiretroviral therapy simplification to dolutegravir monotherapy

Affiliations

¹ Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
² Department of Internal Medicine and Endocrinology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
³ Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Randomized Controlled Trial

Ingeborg Ea Wijting et al. Int J STD AIDS. 2019 Oct.

. 2019 Oct;30(11):1042-1048.

doi: 10.1177/0956462419848962. Epub 2019 Aug 20.

¹ Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
² Department of Internal Medicine and Endocrinology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
³ Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

No abstract available

Keywords: Dolutegravir; bone markers; inflammation markers; lipids; renal markers; tenofovir disoproxil fumarate.

Publication types